Details of Disease

General Information of Disease (ID: DISUPB11)

• Disease Name: B-cell prolymphocytic leukaemia
• Synonyms: BPLL; B-cell prolymphocytic leukemia; B-PLL; B prolymphocytic leukaemia; B prolymphocytic leukemia
• Disease Class: 2A82: Mature B-cell leukaemia
• Definition: A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
• Disease Hierarchy:
  DISD8DU7: Aggressive B-cell non-Hodgkin lymphoma
  DISDPPHX: Prolymphocytic leukaemia
  DISKAXO0: Neoplasm of mature B-cells
  DISUPB11: B-cell prolymphocytic leukaemia
• ICD Code:
  ICD-11: ICD-11: 2A82.1
  ICD-10: ICD-10: C91.3
  Expand ICD-11: '2A82.1
  Expand ICD-10: 'C91.3
• Disease Identifiers:
  MONDO ID: MONDO_0019461
  MESH ID: D054403
  UMLS CUI: C0475801
  MedGen ID: 105396
  Orphanet ID: 86852
  SNOMED CT ID: 128820007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-CD19 CAR-T cells	DMDRYZK	Phase 1/2	CAR T Cell Therapy	[1]
PCAR-019	DM9DR13	Phase 1/2	CAR T Cell Therapy	[2]
CART19 cell	DMM95XS	Phase 1	CAR T Cell Therapy	[3]
CD19/CD22 CAR T-Cells	DMKA2FL	Phase 1	CAR T Cell Therapy	[4]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
• [2] ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
• [3] ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
• [4] ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies